SMIM22

Across TCGA pan-cancer cohorts, SMIM22 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated SMIM22 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher SMIM22 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SMIM22 expression acts as an unfavorable survival marker.

UCEC and LUAD are the cancer types where SMIM22 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.924	1.000	.018	16	view →
LUAD	DFS	Median	All	0.875	0.958	.020	1	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

SMIM22–UCEC (DFS)

Open the UCEC breakdown →